Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 4/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 3/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | HBB | P68871 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18725509 | 0.81 | PDK2 (0.31) | PDK2ALDH1A1KDM4EHPGDGLA | |
| SCHEMBL5072697 | 0.75 | EGFR (0.36) | ALDH1A1KDM4EHPGDGLAGAA | |
| SCHEMBL30850504 | 0.75 | EGFR (0.36) | ALDH1A1KDM4EHPGDGLAGAA | |
| SCHEMBL2009845 | 0.74 | KDM4E (0.35) | ALDH1A1KDM4EHPGDGLAGAA | |
| SCHEMBL99268 | 0.74 | KDM4E (0.35) | ALDH1A1KDM4EHPGDGLAGAA | |
| SCHEMBL5170025 | 0.74 | KDM4E (0.35) | ALDH1A1KDM4EHPGDGLAGAA | |
| SCHEMBL5748053 | 0.74 | KDM4E (0.35) | ALDH1A1KDM4EHPGDGLAGAA | |
| SCHEMBL22430792 | 0.74 | KDM4E (0.35) | ALDH1A1KDM4EHPGDGLAGAA | |
| SCHEMBL840561 | 0.74 | KDM4E (0.35) | ALDH1A1KDM4EHPGDGLAGAA | |
| SCHEMBL1590661 | 0.74 | KDM4E (0.35) | ALDH1A1KDM4EHPGDGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 441 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250283063-A1 | NOVEL CRISPR-CAS12I SYSTEMS AND USES THEREOF | HUIDAGENE THERAPEUTICS CO., LTD. (CN) | 2025-09-11 | — | — | US | claimed |
| EP-4514953-A1 | NOVEL CRISPR-CAS12F SYSTEMS AND USES THEREOF | Huidagene Therapeutics (Singapore) Pte. Ltd. (SG) | 2025-03-05 | — | — | EP | claimed |
| EP-4514954-A1 | NOVEL CRISPR-CAS12I SYSTEMS AND USES THEREOF | Huidagene Therapeutics (Singapore) Pte. Ltd. (SG) | 2025-03-05 | — | — | EP | claimed |
| CN-119421948-A | Novel CRISPR-Cas12f system and application thereof | 辉大(上海)生物科技有限公司 | 2025-02-11 | — | — | CN | claimed |
| CN-119331309-A | Methyl purine ferulic acid aromatized water magnesite composite material and preparation method and application thereof | 江西广源化工有限责任公司 | 2025-01-21 | — | — | CN | claimed |
| CN-118749029-A | Novel CRISPR-Cas12i system and application thereof | 辉大(上海)生物科技有限公司 | 2024-10-08 | — | — | CN | claimed |
| WO-2024094084-A1 | ISCB POLYPEPTIDES AND USES THEREOF | HUIDAGENE THERAPEUTICS CO., LTD. (CN) | 2024-05-10 | — | — | WO | claimed |
| CN-117820252-A | Preparation and detection methods of nitroreductase hemicyanine dye fluorescent probes and visual application of nitroreductase hemicyanine dye fluorescent probes in clinical bacterial identification | 华北理工大学 | 2024-04-05 | — | — | CN | claimed |
| CN-114410836-B | Kit and method for detecting human parvovirus B19 by integrating sample treatment, nucleic acid extraction and multiplex isothermal amplification | 上海交通大学医学院附属仁济医院 | 2024-03-01 | — | — | CN | claimed |
| CN-117460822-A | Novel CRISPR-Cas12i system and application thereof | 辉大基因治疗(新加坡)私人有限公司 | 2024-01-26 | — | — | CN | claimed |
| WO-2013035071-A1 | NOVEL RISK BIOMARKERS FOR LUNG CANCER | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2013-03-14 | — | — | WO | claimed |
| WO-2012178101-A2 | COMPOSITIONS AND METHODS TO REMOVE GENETIC MARKERS USING COUNTER-SELECTION | JOULE UNLIMITED TECHNOLOGIES, INC. (US) | 2012-12-27 | — | — | WO | claimed |
| EP-2278004-B1 | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS INC (US) | 2012-10-31 | — | — | EP | claimed |
| EP-2308994-A1 | Methods for determining a risk to develop cancer | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2011-04-13 | — | — | EP | claimed |
| EP-2226330-A1 | Charge-switch nucleotides | Pacific Biosciences of California, Inc. (US) | 2010-09-08 | — | — | EP | claimed |
| WO-2008069720-A1 | DEVLCE AND METHOD FOR CHOLESTEROL DETERMINATION | HEMOCUE AB (SE) | 2008-06-12 | — | — | WO | claimed |
| US-20070105778-A1 | Methods of screening molecular libraries and active molecules identified thereby | EL-GEWELY MOHAMED R | 2007-05-10 | — | — | US | claimed |
| EP-1515985-A2 | METHODS OF SCREENING MOLECULAR LIBRARIES FOR ACTIVE MOLECULES THAT RESTORE THE FUNCTION OF MUTANT P53 | El-Gewely, Mohammed Raafat (NO) | 2005-03-23 | — | — | EP | claimed |
| WO-2003072600-A2 | METHODS OF SCREENING MOLECULAR LIBRARIES FOR ACTIVE MOLECULES THAT RESTORE THE FUNCTION OF TARGET PROTEINS AND PEPTIDES THAT RESTORE THE FUNCTION OF MUTANT P53 | GARDNER, REBECCA, KATHERINE (GB) | 2003-09-04 | — | — | WO | claimed |
| US-4925901-A | STORAGE STAABILITY, ONIUM ION CATALYST | THE DOW CHEMICAL COMPANY (US) | 1990-05-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250283063-A1 | NOVEL CRISPR-CAS12I SYSTEMS AND USES THEREOF | RBM12, PRR12, HM13 | PDK2 4428/4885PDK4 4036/4885ALDH1A1 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.